Therapeutic antibodies have made an important contribution to modern medicine and drug development pipelines reflect this. However, due to the requirement of a high therapeutic dose, many antibodies are administered by slow intravenous infusion (that can take as long as four hours, in the case of rituximab), in a hospital clinic setting. This is not only inconvenient for patients but limits administration to clinical settings which can be costly.

A number of pharmaceutical and biotechnology companies are presently seeking novel ways of increasing the therapeutic dose for their proprietary antibodies to levels as high as 200 mg/ml. Through the application of Arestat™ technologies, Arecor has demonstrated that higher concentrations of proteins can be maintained in storage without degradation or aggregation typically associated with such formulations. Arecor is working with a range of approved recombinant therapeutic proteins at significantly higher doses than the marketed brands thereby creating opportunities for new routes of administration for these formulations.